Research by Germany-based biotech company PharmaInformatic compared study results on drug-uptake (oral bioavailability) in animals and humans for a wide range of approved and established drugs has claimed that sole reliance on drug-uptake in animal trials can be misleading.

Results demonstrated that oral bioavailability in animals is not in line with the values reported for humans. For instance, Aripiprazole and Esomeprazole, which are the most sold drugs in 2013, possess low oral bioavailability in animals, while it is high in humans.

"Results demonstrated that oral bioavailability in animals is not in line with the values reported for humans."

Most successful commercial drugs such as blockbuster treatments also showed large difference in the values, which are said to have annual sales of around $1bn.

During the drug development process, most of the compounds are usually tested on rats, dogs, monkeys and mice to test for the effectiveness and possession of sufficient oral bioavailability. Further drug development is put on hold if the bioavailability is too low.

According to PharmaInformatic, animal trials on drug-uptakes are mostly replaced by an alternative system such as IMPACT-F, which is used to evaluate human oral bioavailability in different therapeutic areas such as diabetes, inflammation, antivirals, autoimmune diseases and cancer. The system is said to evaluate oral bioavailability more efficiently in humans, compared to animal trials.

It is expected to increase the prospects of human clinical trials, as the optimum oral dose for first-in-human clinical trials can be determined much more accurately.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.